BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...
PFE along with BioNTech SE BNTX announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of $93.00. The company’s shares closed last Friday ...
Assembly Biosciences reported interim results from its Phase 1a study of ABI-5366, a long-acting HSV inhibitor for recurrent ...
BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.
Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Eli Lilly & Co, and AbbVie. According to TipRanks, Flynn has an average return of 12.6% and a 63.89% success rate on ...
Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
EMA’s human medicines committee recommends marketing approval for Pfizer & BioNTech’s Omicron KP.2-adapted Covid-19 vaccine: New York Monday, September 23, 2024, 10:00 Hrs [IS ...
Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...
BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit ...